Results 41 to 50 of about 7,409 (168)
Use of Glucagon‐Like Peptide‐1 Receptor Agonists in Danish Adolescents and Young Adults 2018–2025
Obesity, EarlyView.ABSTRACT Objective Use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) has increased rapidly following approval for obesity treatment, but data on their use in younger populations remain limited. We examined trends in GLP‐1RA use among 12– to 24‐year‐olds in Denmark during 2018–2025.
Helene Kildegaard +4 more
wiley +1 more source
Bardet-Biedl Syndrome: A Case Study
, 2015 It is frequently difficult to find an optimal nutritional treatment for children who have rare genetic conditions with multisystem abnormalities because of the complexity of symptoms and the lack of evidence based treatments.
Fracchia, Caitlin
core +2 more sources
Pediatric Investigation, EarlyView.Monogenic and syndromic obesity in children often arises from defects in the leptin–melanocortin pathway. Understanding these rare genetic causes not only clarifies mechanisms of appetite regulation but also enables precision therapies, offering hope beyond lifestyle interventions.
Hadel Khalil +2 more
wiley +1 more source
Choroidal neovascularization in Bardet-Biedl syndrome
, 2013 Purpose: To describe a case of choroidal neovascularization in a young patient with genetically-proven Bardet-Biedl syndrome. Methods: Case description with fundus and anatomical photography and optical coherence tomography. Patients: Single patient case
Fortun, Jorge +4 more
core +1 more source
Case Study of Bardet-Biedl Syndrome with Fetal Lobulation and Focal Segmental Glomerulosclerosis
Endocrinology Research and Practice, 2008 Bardet-Biedl syndrome is a genetic autosomal recessive disease characterized by abdominal obesity, mental retardation, dysmorphic extremities, retinal dystrophy or pigmentary retinopathy, hypogonadism or hypogenitalism, and kidney involvement.
Yılmaz Tabel +3 more
doaj +2 more sources
Case Reports in Ophthalmological Medicine, 2022 Bardet–Biedl syndrome is a rare autosomal recessive form of syndromic obesity which is characterized by retinal degeneration, obesity, polydactyly, cognitive impairment, and renal and urogenital anomalies.
Roghayeh Dehghan +3 more
doaj +1 more source
Amylin analogues as a novel perspective in anti‐obesity therapy
British Journal of Pharmacology, EarlyView.Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley +1 more source
Stem Cell Research, 2021 Bardet-Biedl syndrome (BBS) is primarily a multisystem nonmotile ciliopathy. In this study, we describe the successful establishment and characterization of an iPSC line from a patient diagnosed with BBS who was compound heterozygous for the BBS7 ...
Qian Fu +6 more
doaj +1 more source
Journal of Clinical Periodontology, EarlyView.ABSTRACT Aims This systematic review assesses current evidence on the management of non‐plaque (dental biofilm)‐induced gingival diseases and conditions (NPIGDs), including (i) inflammatory and immune conditions, (ii) neoplasms and (iii) gingival pigmentations.
Maria Clotilde Carra +5 more
wiley +1 more source
Setmelanotide in Bardet‐Biedl Syndrome: A Case Report
Pediatric Dermatology, EarlyView.ABSTRACT Setmelanotide is a melanocortin‐4‐receptor agonist used for the treatment of hyperphagia in the genetic obesity syndrome Bardet‐Biedl. Presented is a case of diffuse hyperpigmentation in a patient treated with setmelanotide, which represents the most common side effect of this medication.
Shelby Smith +2 more
wiley +1 more source